Myeloma Crowd Radio

Upcoming Shows

Our Next Show: ICER’s Value Recommendations Potential Impact on the Cost of New Drugs and Patient Access with Steven Pearson, MD, MSc, President of ICER on Tuesday, May 24 @ 11 am EST


Tuesday, May 24, 8 am PST, 9 am MST, 10 am CST, 11 am EST

Call In by Phone to Listen Live: (347) 637-2631 or Listen Live Via Computer

The Institute for Clinical and Economic Review’s (ICER) Midwest Comparative Effective Public Advisory Council (CEPAC) will hold is inaugural meeting on May 26, 2016 in St. Louis “to discuss the comparative clinical effectiveness and value of therapies of multiple myeloma.”  The goal is to create recommendations that health insurers (or payers) will use to determine reimbursement levels for drugs used in myeloma treatment.  Since the public announcement of ICER’s plan in February 2016, the draft reports have been strongly criticized by myeloma specialists, pharmaceutical companies, and more recently, patient advocates.  Dr. Steven Pearson will discuss ICER’s perspective, addressing critics of ICER’s methodology, process, definitions of value, and, as of now, the lack of inclusion of patient views.

Steven D. Pearson, MD, MSc is the Founder and President of the Institute for Clinical and Economic Review (or ICER), which, according to its website, “is an independent non-profit organization that evaluates the evidence on the value of medical tests, treatments, and delivery system innovations and moves that evidence into action to improve patient care and control costs.” He received his MD at the University of California, San Francisco School of Medicine, completed his residency in internal medicine at Brigham and Women’s Hospital in Boston, and obtained a Master of Science Degree in Health Policy and Management at the Harvard School of Public Health.  His experience included serving in many advisory and leadership roles in academia and government, including a fellowship with the National Institute for Health and Clinical Excellence (also known as NICE) in the United Kingdom.  He has served as Special Advisor to the Centers for Medicare and Medicaid Services, Senior Fellow at America’s Health Insurance Plans, Vice Chair of the Medicare Evidence Development and Coverage Advisory Committee from 2007-2009, and was a Member of the Board of Directors of Health Technology Assessment International from 2010-2013.

Myeloma Crowd Radio Episodes